ATE555078T1 - Verfahren und zwischenprodukte - Google Patents

Verfahren und zwischenprodukte

Info

Publication number
ATE555078T1
ATE555078T1 AT01975197T AT01975197T ATE555078T1 AT E555078 T1 ATE555078 T1 AT E555078T1 AT 01975197 T AT01975197 T AT 01975197T AT 01975197 T AT01975197 T AT 01975197T AT E555078 T1 ATE555078 T1 AT E555078T1
Authority
AT
Austria
Prior art keywords
intermediate products
products
Prior art date
Application number
AT01975197T
Other languages
English (en)
Inventor
Ann Eldridge
Johann Hiebl
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE555078T1 publication Critical patent/ATE555078T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C07C319/24Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
AT01975197T 2000-09-12 2001-09-12 Verfahren und zwischenprodukte ATE555078T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23178400P 2000-09-12 2000-09-12
PCT/US2001/028443 WO2002022554A1 (en) 2000-09-12 2001-09-12 Process and intermediates

Publications (1)

Publication Number Publication Date
ATE555078T1 true ATE555078T1 (de) 2012-05-15

Family

ID=22870636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01975197T ATE555078T1 (de) 2000-09-12 2001-09-12 Verfahren und zwischenprodukte

Country Status (11)

Country Link
US (2) US6570024B2 (de)
EP (1) EP1322597B1 (de)
JP (1) JP4886961B2 (de)
AR (1) AR030612A1 (de)
AT (1) ATE555078T1 (de)
AU (1) AU2001294549A1 (de)
CY (1) CY1112871T1 (de)
DK (1) DK1322597T3 (de)
ES (1) ES2383792T3 (de)
PT (1) PT1322597E (de)
WO (1) WO2002022554A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
PL1819359T3 (pl) * 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
EP2126127B1 (de) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Verwendung von anti-egfr-antikörpern bei der behandlung von durch egfr-mutanten vermittelten krankheiten
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
PT2437785E (pt) 2009-06-04 2015-04-20 Novartis Ag Método de identificação de sítios para conjugação de igg
EP2448966B1 (de) 2009-07-03 2018-11-14 Avipep Pty Ltd Immunkonjugate und verfahren zu ihrer herstellung
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
WO2011075786A1 (en) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
SI3415531T1 (sl) 2011-05-27 2023-12-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) - vezni proteini
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2014262566A1 (en) 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
JP2016538283A (ja) 2013-11-13 2016-12-08 ザイムワークス,インコーポレイテッド Egfr及び/またはher2を標的にする一価抗原結合性構築物及びその使用
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
CN113710674B (zh) * 2019-04-18 2024-03-15 意迪那有限公司 制备含硫醇或二硫化物的美登素酯及其中间体的非对映选择性方法
WO2022248870A1 (en) 2021-05-28 2022-12-01 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
WO2023057893A1 (en) 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
JPS61112042A (ja) * 1985-07-31 1986-05-30 Wakunaga Seiyaku Kk 架橋試薬として適当な化合物
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP3408158B2 (ja) * 1998-07-17 2003-05-19 大日本製薬株式会社 スルトプリド誘導体及び抗スルトプリド抗体
US6573074B2 (en) * 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Also Published As

Publication number Publication date
EP1322597A4 (de) 2005-10-19
EP1322597A1 (de) 2003-07-02
CY1112871T1 (el) 2016-04-13
AU2001294549A1 (en) 2002-03-26
JP2004509094A (ja) 2004-03-25
ES2383792T3 (es) 2012-06-26
AR030612A1 (es) 2003-08-27
US20020156318A1 (en) 2002-10-24
US20040014980A1 (en) 2004-01-22
EP1322597B1 (de) 2012-04-25
WO2002022554A1 (en) 2002-03-21
DK1322597T3 (da) 2012-07-02
PT1322597E (pt) 2012-06-01
JP4886961B2 (ja) 2012-02-29
US6570024B2 (en) 2003-05-27
US6884874B2 (en) 2005-04-26

Similar Documents

Publication Publication Date Title
ATE283273T1 (de) Hemisynthetisches verfahren und dessen zwischenprudukte
DE60140895D1 (de) Zusammensetzung und verfahren
DE60139930D1 (de) Desinfizieruns- und desodorierungsverfahren
CY2008006I1 (el) Παραγωγα τροπανιου χρησιμα στη θepαπευτικη
DE60129522D1 (de) Gipszusammensetzungen und dazugehörende verfahren
FI19992360L (fi) Tuote ja menetelmä sen valmistamiseksi
DE60115902D1 (de) Osteoimplantat und verfahren zu seiner herstellung
DE60134496D1 (de) Polyesterverfahren
DE60138648D1 (de) Modulare atemgeräte und verfahren zum umbau derselben
DE60112988D1 (de) Kabelbaum und Herstellungsverfahren
DE59913180D1 (de) Produktebestellungsverfahren und system
DE60100770D1 (de) Doppelbahniger Förderbandreinigungsapparat und Verfahren
ATA10852001A (de) Bauelement und verfahren zu seiner herstellung
DE60229770D1 (de) Reibungsreduzierende zusammensetzung und verfahren
DE60134540D1 (de) Töchiometrie aufweisender isolierschicht und verfahren zur herstellung
ATE286658T1 (de) Teigformmaschine und verfahren
DE60017012D1 (de) Orginalitätsverschluss und Herstellungverfahren
DE60116486D1 (de) Gallengangstent und verfahren zu seiner herstellung
DK1322597T3 (da) Fremgangsmåde og intermediære
DE69904731D1 (de) Feinzerkleinerer und feinzerkleinerungsverfahren
ATE322174T1 (de) Gefrorene süsswaren und herstellungsverfahren
DE60106372D1 (de) Redox System und Verfahren
EP1347866A4 (de) Holzprodukte und verfahren zur herstellung derselben
EP1299337A4 (de) Hydroxyphenstatin und seine promedikamente
DE60208700D1 (de) Schälgerät und zugehörige verfahren